분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2010-10-11 11:17:50 , Hit : 2567
 First Clinical Trial of Gene Therapy for Muscular Dystrophy Lends Insight Into the Disease


ScienceDaily (Oct. 7, 2010) — A clinical trial designed to replace the genetic defect causing the most common form of muscular dystrophy has uncovered an unexpected aspect of the disease. The trial, based on therapy designed by scientists at the University of North Carolina at Chapel Hill School of Medicine, showed that some patients mount an immune response to the dystrophin protein even before they have received the gene therapy.


--------------------------------------------------------------------------------

See Also:
Health & Medicine
Gene Therapy
Muscular Dystrophy
Personalized Medicine
Genes
Diseases and Conditions
Human Biology
Reference
Spinal muscular atrophy
Vector (biology)
Huntington's disease
Clinical trial
The puzzling results, which came from trials at Columbus Children's Hospital in Ohio, suggest that the immune systems of a number of patients -- once thought to be completely devoid of the dystrophin protein -- are actually primed by the prior existence of tiny amounts of this important component of muscle.

Published in the New England Journal of Medicine, the study demonstrates how such careful and critical observation in early clinical trials of new therapies can yield new insights into the causes of even the "simplest" single gene disorders.

"These findings are going to be studied intensely going forward, and should help us to understand how to better tailor our treatment approaches to suit the patients' needs," said study author R. Jude Samulski, professor of pharmacology and director of the Gene Therapy Center at UNC.

Duchenne muscular dystrophy is a genetic disease that begins in early childhood, causes progressive muscle weakness, and usually leads to death by the age of twenty from respiratory or cardiac muscle failure. The illness, which primarily affects boys, occurs when a gene on the X chromosome fails to make the essential muscle protein dystrophin. Currently, the best medical therapy can only slow its progression.

The use of gene therapy to correct such single gene disorders has been explored for over two decades and has been met with a number of challenges. In the case of muscular dystrophy, the dystrophin gene is far too large to fit into the typical virus used to carry it into the patient's cells. So collaborator Xiao Xiao, PhD from UNC Eshelman School of Pharmacy engineered a smaller yet functional version of the gene -- called a minigene -- to place within the viral carrier. His virus of choice was adeno-associated virus or AAV, a small virus that most humans are exposed to at some point in life.

In the first trial of this form of gene therapy, which began in 2006, six boys with muscular dystrophy received the virus containing the dystrophin minigene. A phase I trial, the goals of the study were to assess the efficacy and safety of the new approach. The replacement genes were injected into the bicep in one arm and a placebo was injected into the other arm of each of the patients.

The researchers found that the immune response to the gene varied from patient to patient, perhaps in part because the patients harbored different amounts of "revertant" dystrophin fibers, fibers that have escaped the fate of their mutation. Further studies are needed, but this finding suggests that some patients may benefit from immunosuppression prior to receiving gene therapy.

"We can now use this new information to adapt our approach to make gene therapy more likely to succeed," said Samulski. "Right now we are searching for a way to cure this disease, not just care for it, but truly cure it. So we realize that this effort is going to be an iterative process, with the accumulation of a number of lessons along the way to help us succeed."

One lesson from this study suggests that keeping a close eye on the immune-response profiles of patients could help to enhance the success of not just gene therapy, but also other therapies aimed at restoring dystrophin activity.

The research was funded in part by the Muscular Dystrophy Association and UNC startup biotech company Asklepios BioPharmaceutical Inc. Study co-authors from UNC include Dawn Bowles, PhD; Steven Gray, PhD; Chengwin Li, PhD; and Xiao Xiao, PhD.

Editor's Note: This article is not intended to provide medical advice, diagnosis or treatment.

Email or share this story:| More
--------------------------------------------------------------------------------

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by University of North Carolina School of Medicine, via EurekAlert!, a service of AAAS.

--------------------------------------------------------------------------------

Journal Reference:

Jerry R. Mendell, Katherine Campbell, Louise Rodino-Klapac, Zarife Sahenk, Chris Shilling, Sarah Lewis, Dawn Bowles, Steven Gray, Chengwen Li, Gloria Galloway, Vinod Malik, Brian Coley, K. Reed Clark, Juan Li, Xiao Xiao, Jade Samulski, Scott W. McPhee, R. Jude Samulski, Christopher M. Walker. Dystrophin Immunity in Duchenne's Muscular Dystrophy. New England Journal of Medicine, 2010; 363 (15): 1429 DOI: 10.1056/NEJMoa1000228







  First Clinical Trial of Gene Therapy for Muscular Dystrophy Lends Insight Into the Disease  이성욱 2010/10/11 2567
806   Hepatitis C virus infection linked to fat enzyme in liver cells  이성욱 2010/10/14 3214
805   Hepatitis C Virus Infection Linked to Fat Enzyme in Liver Cells  이성욱 2010/10/15 2978
804   Roche hepatitis C drug appears safe in combination  이성욱 2010/10/17 3001
803   헤르페스 감염 메커니즘 밝혀져  이성욱 2010/10/17 5890
802   Study points to possible gene therapy for depression  이성욱 2010/10/22 2500
801   More than a chicken, fewer than a grape - Exact tally of human genes remains elusive  이성욱 2010/10/25 2565
800   Strides Against Hepatitis C Open Door to Blockbusters  이성욱 2010/11/02 2572
799   Black patients fare well on Vertex hepatitis C drug  이성욱 2010/11/02 2715
798   Too Much SP2 Protein Turns Stem Cells Into “Evil Twin” Tumor-forming Cancer Cells  관리자 2010/11/02 3895
797   NC State Develops More Precise Genetic ‘Off Switches’  이성욱 2010/11/03 2636
796   Breakthrough in cancer vaccine research  이성욱 2010/11/08 2690
795   DNA sequence may be lost in translation  이성욱 2010/11/10 2789
794   Lung Cancer in Smokers, Nonsmokers May Be a Different Disease  이성욱 2010/11/10 2579
793   Why brain tumors hard to treat  이성욱 2010/11/23 2923
792   Vertex submits application for hepatitis C drug  이성욱 2010/11/25 3432
791   Tumours grow their own blood vessels  이성욱 2010/11/25 2363
790   Top 5 papers of 2010  이성욱 2010/12/10 2332
789   Microbe gets toxic response  이성욱 2010/12/10 2471
788   Basel Declaration defends animal research  이성욱 2010/12/10 2373

[이전 10개] [1]..[21][22][23] 24 [25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN